GSK Ramps Up Neuroscience Investment With ABL Brain Shuttle Deal
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.